| answer text |
<p>The Government invested over £300 million in 2020 to secure and scale-up the UK’s
manufacturing capabilities to respond to this pandemic, including:</p><p>- £127 million
towards the Cell and Gene Therapy Catapult Braintree in Essex;</p><p>- £93 million
to accelerate the completion and expanded role of the Vaccine Manufacturing Innovation
Centre in Oxfordshire;</p><p>- £4.7 million for skills training through the Advanced
Therapies Skills Training Network, which will be delivered through both virtual and
physical centres;</p><p>- £8.75 million for the set-up of the rapid deployment facility
at Oxford Biomedica in Oxfordshire; and</p><p>- £65.5 million for the manufacture
of the University of Oxford / AstraZeneca vaccine.</p><p> </p><p>In addition to the
above, we have also funded the fill and finish of vaccines through a contract with
Wockhardt in Wrexham, North Wales, as well as the expansion of the Valneva factory
in Livingston, Scotland. However, we are not able to give further details on these
two developments owing to commercial confidentiality.</p>
|
|
